Sterling Capital Management LLC Purchases 4,665 Shares of DaVita Inc. $DVA

Sterling Capital Management LLC raised its position in shares of DaVita Inc. (NYSE:DVA) by 104.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 9,140 shares of the company’s stock after acquiring an additional 4,665 shares during the quarter. Sterling Capital Management LLC’s holdings in DaVita were worth $1,599,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of DVA. Berkshire Hathaway Inc bought a new position in shares of DaVita during the 2nd quarter worth approximately $6,425,269,000. BlackRock Inc. bought a new stake in shares of DaVita in the 2nd quarter valued at $547,520,000. Dimensional Fund Advisors LP increased its stake in shares of DaVita by 5.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,145,436 shares of the company’s stock valued at $176,037,000 after acquiring an additional 56,336 shares in the last quarter. Bank of America Corp DE bought a new stake in shares of DaVita in the 2nd quarter valued at $145,057,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of DaVita during the 2nd quarter valued at $101,127,000. 90.12% of the stock is currently owned by institutional investors and hedge funds.

DaVita Price Performance

DVA opened at $183.59 on Tuesday. The company has a market capitalization of $11.71 billion, a price-to-earnings ratio of 15.02, a P/E/G ratio of 0.48 and a beta of 0.80. The firm’s fifty day moving average price is $180.60 and its two-hundred day moving average price is $174.99. DaVita Inc. has a 1 year low of $101.00 and a 1 year high of $247.49.

DaVita (NYSE:DVA) last posted its earnings results on Tuesday, August 4th. The company reported $4.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.88 by $0.14. The firm had revenue of $3.55 billion during the quarter, compared to analyst estimates of $3.50 billion. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. The business’s revenue was up 5.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.95 EPS. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, equities analysts anticipate that DaVita Inc. will post 14.57 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the stock. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $265.00 target price on shares of DaVita in a research note on Wednesday, August 5th. Weiss Ratings raised shares of DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Friday, October 9th. TD Cowen reaffirmed a “buy” rating on shares of DaVita in a research note on Wednesday, October 21st. UBS Group upped their price objective on shares of DaVita from $235.00 to $270.00 and gave the company a “buy” rating in a report on Friday, July 10th. Finally, Oppenheimer set a $220.00 price objective on shares of DaVita in a research report on Friday, August 7th. Four equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $233.43.

DaVita Profile

DaVita Inc (NYSE: DVA) is a health care services company focused on kidney care. Through its DaVita Kidney Care business, the company provides outpatient dialysis treatments for people with chronic kidney failure, including in-center hemodialysis, home dialysis and related clinical support services.

DaVita also offers integrated kidney care programs intended to support patients across the stages of chronic kidney disease. Its services may include care coordination, disease management, education, transplant support and other services designed to improve clinical outcomes and help manage the needs of patients with complex kidney conditions.

The company operates a network of dialysis centers and related facilities in the United States and serves patients in select international markets.